Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2013 - 2018)

Alnylam Pharmaceuticals (ALNY) has 6 years of Other Accumulated Expenses data on file, last reported at $23.6 million in Q4 2018.

• Quarterly Other Accumulated Expenses rose 117.66% year-over-year to $23.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $23.6 million (up 117.66% YoY) and the FY2018 annual result came in at $23.6 million, up 117.66% from the prior year.
• Other Accumulated Expenses rose to $23.6 million in Q4 2018, from $10.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $25.4 million in Q1 2014 to a low of $3.8 million in Q4 2014.
• A 5-year average of $13.5 million and a median of $11.7 million in 2016 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2016 — Other Accumulated Expenses jumped 154.34% — and 2017, when it fell 14.02%.
• Tracing ALNY's Other Accumulated Expenses over 5 years: stood at $3.8 million in 2014, then jumped by 30.38% to $5.0 million in 2015, then surged by 154.34% to $12.6 million in 2016, then slipped by 14.02% to $10.9 million in 2017, then jumped by 117.66% to $23.6 million in 2018.
• The last three Other Accumulated Expenses figures came in at $23.6 million (Q4 2018), $10.9 million (Q4 2017), and $12.6 million (Q4 2016), per Business Quant data.